TY - JOUR
T1 - Acid Load and Phosphorus Homeostasis in CKD
AU - Chronic Renal Insufficiency Cohort (CRIC) Study Investigators
AU - Chronic Renal Insufficiency Cohort (CRIC) Study Investigators
AU - Khairallah, Pascale
AU - Isakova, Tamara
AU - Asplin, John
AU - Hamm, Lee
AU - Dobre, Mirela
AU - Rahman, Mahboob
AU - Sharma, Kumar
AU - Leonard, Mary
AU - Miller, Edgar
AU - Jaar, Bernard
AU - Brecklin, Carolyn
AU - Yang, Wei
AU - Wang, Xue
AU - Feldman, Harold
AU - Wolf, Myles
AU - Scialla, Julia J.
AU - Appel, Lawrence J.
AU - Feldman, Harold I.
AU - Go, Alan S.
AU - He, Jiang
AU - Kusek, John W.
AU - Lash, James P.
AU - Ojo, Akinlolu
AU - Rahman, Mahboob
AU - Townsend, Raymond R.
N1 - Funding Information:
The CRIC Study Investigators include Lawrence J. Appel, MD, MPH, Harold I. Feldman, MD, MSCE, Alan S. Go, MD, Jiang He, MD, PhD, John W. Kusek, PhD, James P. Lash, MD, Akinlolu Ojo, MD, PhD, Mahboob Rahman, MD, and Raymond R. Townsend, MD. We acknowledge the contributions of CRIC participants and staff. Support: This study was supported in part by grant K23DK095949 (to Dr Scialla) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Dr Khairallah was supported in part by a Stead Resident Research Award from the Duke University Department of Medicine. Dr Isakova was supported by grant R01DK110087 from the NIDDK . A statistical consultation was obtained from Huiman Barnhart, PhD, through the Duke O’Brien Center for Kidney Disease Research ( P30DK096493 ). Funding for the CRIC Study was obtained under a cooperative agreement from the NIDDK ( U01DK060990 , U01DK060984 , U01DK061022 , U01DK061021 , U01DK061028 , U01DK060980 , U01DK060963 , and U01DK060902 ). In addition, this work was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award National Institutes of Health (NIH)/National Center or Advancing Translational Sciences (NCATS) UL1TR000003 , Johns Hopkins University UL1 TR-000424 , University of Maryland General Clinical Research Center M01 RR-16500 , Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the NCATS component of the NIH and NIH Roadmap for Medical Research, Michigan Institute for Clinical and Health Research UL1TR000433 , University of Illinois at Chicago Clinical and Translational Science Award UL1RR029879, Tulane Center of Biomedical Research Ethics for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036 , Kaiser Permanente NIH/National Center for Research Resources University of California San Francisco−Clinical and Translational Science Institute UL1 RR-024131. The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH. The funders had no direct role in study design, data analysis, interpretation, manuscript writing, or the decision to submit the report for publication. Financial Disclosure: Dr Isakova has received consulting fees from Kyowa Hakko Kirin. The other authors declare that they have no other relevant financial interests. Contributions: Research idea and study design: PK, TI, JA, HF, MW, JJS; data acquisition: TI, JA, LH, MR, ML, EM, BJ, CB, HF, MW, JJS; data analysis/interpretation: PK, TI, JA, LH, MD, MR, KS, ML, HF, MW, JJS; statistical analysis: PK, WY, XW, JJS; supervision or mentorship: HF, MW, JJS. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. Peer Review: Evaluated by 4 external peer reviewers, a statistician, and an Acting Editor-in-Chief.
Funding Information:
Support: This study was supported in part by grant K23DK095949 (to Dr Scialla) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Dr Khairallah was supported in part by a Stead Resident Research Award from the Duke University Department of Medicine. Dr Isakova was supported by grant R01DK110087 from the NIDDK. A statistical consultation was obtained from Huiman Barnhart, PhD, through the Duke O'Brien Center for Kidney Disease Research (P30DK096493). Funding for the CRIC Study was obtained under a cooperative agreement from the NIDDK (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, and U01DK060902). In addition, this work was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award National Institutes of Health (NIH)/National Center or Advancing Translational Sciences (NCATS) UL1TR000003, Johns Hopkins University UL1 TR-000424, University of Maryland General Clinical Research Center M01 RR-16500, Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the NCATS component of the NIH and NIH Roadmap for Medical Research, Michigan Institute for Clinical and Health Research UL1TR000433, University of Illinois at Chicago Clinical and Translational Science Award UL1RR029879, Tulane Center of Biomedical Research Ethics for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036, Kaiser Permanente NIH/National Center for Research Resources University of California San Francisco?Clinical and Translational Science Institute UL1 RR-024131. The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH. The funders had no direct role in study design, data analysis, interpretation, manuscript writing, or the decision to submit the report for publication.
Publisher Copyright:
© 2017 National Kidney Foundation, Inc.
PY - 2017/10
Y1 - 2017/10
N2 - Background The kidneys maintain acid-base homeostasis through excretion of acid as either ammonium or as titratable acids that primarily use phosphate as a buffer. In chronic kidney disease (CKD), ammoniagenesis is impaired, promoting metabolic acidosis. Metabolic acidosis stimulates phosphaturic hormones, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF-23) in vitro, possibly to increase urine titratable acid buffers, but this has not been confirmed in humans. We hypothesized that higher acid load and acidosis would associate with altered phosphorus homeostasis, including higher urinary phosphorus excretion and serum PTH and FGF-23. Study Design Cross-sectional. Setting & Participants 980 participants with CKD enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study. Predictors Net acid excretion as measured in 24-hour urine, potential renal acid load (PRAL) estimated from food frequency questionnaire responses, and serum bicarbonate concentration < 22 mEq/L. Outcome & Measurements 24-hour urine phosphorus and calcium excretion and serum phosphorus, FGF-23, and PTH concentrations. Results Using linear and log-linear regression adjusted for demographics, kidney function, comorbid conditions, body mass index, diuretic use, and 24-hour urine creatinine excretion, we found that 24-hour urine phosphorus excretion was higher at higher net acid excretion, higher PRAL, and lower serum bicarbonate concentration (each P < 0.05). Serum phosphorus concentration was also higher with higher net acid excretion and lower serum bicarbonate concentration (each P = 0.001). Only higher net acid excretion associated with higher 24-hour urine calcium excretion (P < 0.001). Neither net acid excretion nor PRAL was associated with FGF-23 or PTH concentrations. PTH, but not FGF-23, concentration (P = 0.2) was 26% (95% CI, 13%-40%) higher in participants with a serum bicarbonate concentration <22 versus ≥22 mEq/L (P < 0.001). Primary results were similar if stratified by estimated glomerular filtration rate categories or adjusted for iothalamate glomerular filtration rate (n = 359), total energy intake, dietary phosphorus, or urine urea nitrogen excretion, when available. Limitations Possible residual confounding by kidney function or nutrition; urine phosphorus excretion was included in calculation of the titratable acid component of net acid excretion. Conclusions In CKD, higher acid load and acidosis associate independently with increased circulating phosphorus concentration and augmented phosphaturia, but not consistently with FGF-23 or PTH concentrations. This may be an adaptation that increases titratable acid excretion and thus helps maintain acid-base homeostasis in CKD. Understanding whether administration of base can lower phosphorus concentrations requires testing in interventional trials.
AB - Background The kidneys maintain acid-base homeostasis through excretion of acid as either ammonium or as titratable acids that primarily use phosphate as a buffer. In chronic kidney disease (CKD), ammoniagenesis is impaired, promoting metabolic acidosis. Metabolic acidosis stimulates phosphaturic hormones, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF-23) in vitro, possibly to increase urine titratable acid buffers, but this has not been confirmed in humans. We hypothesized that higher acid load and acidosis would associate with altered phosphorus homeostasis, including higher urinary phosphorus excretion and serum PTH and FGF-23. Study Design Cross-sectional. Setting & Participants 980 participants with CKD enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study. Predictors Net acid excretion as measured in 24-hour urine, potential renal acid load (PRAL) estimated from food frequency questionnaire responses, and serum bicarbonate concentration < 22 mEq/L. Outcome & Measurements 24-hour urine phosphorus and calcium excretion and serum phosphorus, FGF-23, and PTH concentrations. Results Using linear and log-linear regression adjusted for demographics, kidney function, comorbid conditions, body mass index, diuretic use, and 24-hour urine creatinine excretion, we found that 24-hour urine phosphorus excretion was higher at higher net acid excretion, higher PRAL, and lower serum bicarbonate concentration (each P < 0.05). Serum phosphorus concentration was also higher with higher net acid excretion and lower serum bicarbonate concentration (each P = 0.001). Only higher net acid excretion associated with higher 24-hour urine calcium excretion (P < 0.001). Neither net acid excretion nor PRAL was associated with FGF-23 or PTH concentrations. PTH, but not FGF-23, concentration (P = 0.2) was 26% (95% CI, 13%-40%) higher in participants with a serum bicarbonate concentration <22 versus ≥22 mEq/L (P < 0.001). Primary results were similar if stratified by estimated glomerular filtration rate categories or adjusted for iothalamate glomerular filtration rate (n = 359), total energy intake, dietary phosphorus, or urine urea nitrogen excretion, when available. Limitations Possible residual confounding by kidney function or nutrition; urine phosphorus excretion was included in calculation of the titratable acid component of net acid excretion. Conclusions In CKD, higher acid load and acidosis associate independently with increased circulating phosphorus concentration and augmented phosphaturia, but not consistently with FGF-23 or PTH concentrations. This may be an adaptation that increases titratable acid excretion and thus helps maintain acid-base homeostasis in CKD. Understanding whether administration of base can lower phosphorus concentrations requires testing in interventional trials.
KW - Acid-base
KW - FE
KW - acid load
KW - acidosis
KW - chronic kidney disease (CKD)
KW - fibroblast growth factor 23 (FGF-23)
KW - parathyroid hormone (PTH)
KW - phosphaturic hormones
KW - phosphorus
KW - phosphorus excretion
KW - phosphorus homeostasis
KW - physiology
KW - potential renal acid load (PRAL)
UR - http://www.scopus.com/inward/record.url?scp=85021065520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021065520&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2017.04.022
DO - 10.1053/j.ajkd.2017.04.022
M3 - Article
C2 - 28645705
AN - SCOPUS:85021065520
SN - 0272-6386
VL - 70
SP - 541
EP - 550
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 4
ER -